Xeris Biopharma Holdings, Inc. (LON:0A8E)

Xeris Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	291.85	203.07	163.91	110.25	49.59
Revenue Growth (YoY)	43.72%	23.89%	48.68%	122.32%	142.67%
Cost of Revenue	42.57	36.83	28.65	22.63	13.32
Gross Profit	249.28	166.24	135.27	87.61	36.27
Selling, General & Admin	182.37	163.48	146.1	137.75	125.72
Depreciation & Amortization Expenses	10.84	10.84	10.84	10.84	0.55
Research & Development	31.17	25.56	22.34	20.97	25.16
Operating Income	24.9	-33.65	-44.01	-81.94	-115.16
Interest Income	4.74	5.32	4.75	2.58	0.31
Interest Expense	-29.08	-30.49	-26.61	-14.1	-7.18
Other Non-Operating Income (Expense)	-	1.71	2.36	-2.62	-0.7
Total Non-Operating Income (Expense)	-24.34	-23.46	-19.49	-14.14	-7.57
Pretax Income	0.55	-57.1	-63.5	-96.08	-122.73
Provision for Income Taxes	-	-2.27	-1.25	-1.42	-
Net Income	0.55	-54.84	-62.26	-94.66	-122.73
Net Income to Common	0.55	-54.84	-62.26	-94.66	-122.73
Shares Outstanding (Basic)	160	147	138	136	79
Shares Outstanding (Diluted)	173	147	138	136	79
Shares Change (YoY)	17.69%	6.61%	1.51%	71.62%	85.32%
EPS (Basic)	0.00	-0.37	-0.45	-0.70	-1.55
EPS (Diluted)	0.00	-0.37	-0.45	-0.70	-1.55
Free Cash Flow	27.93	-37.85	-49.29	-103.42	-96.62
Free Cash Flow Per Share	0.16	-0.26	-0.36	-0.76	-1.22
Gross Margin	85.41%	81.86%	82.52%	79.47%	73.14%
Operating Margin	8.53%	-16.57%	-26.85%	-74.32%	-232.22%
Profit Margin	0.19%	-27.00%	-37.98%	-85.86%	-247.48%
FCF Margin	9.57%	-18.64%	-30.07%	-93.80%	-194.84%
EBITDA	37.05	-21.58	-31.68	-69.7	-113.28
EBITDA Margin	12.70%	-10.62%	-19.33%	-63.22%	-228.43%
EBIT	24.9	-33.65	-44.01	-81.94	-115.16
EBIT Margin	8.53%	-16.57%	-26.85%	-74.32%	-232.22%
Effective Tax Rate	0.00%	3.97%	1.97%	1.48%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.